Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche launches "future proof" Chlamydia test in Europe

This article was originally published in Clinica

Executive Summary

Roche Diagnostics has launched its Cobas TaqMan CT Test v2.0 in Europe. It CE marked the diagnostic, for detecting Chlamydia trachomatis, in June. Basel, Switzerland-based Roche claims the test is "future-proof", meaning it still produces reliable results even when mutations occur in the bacteria's cryptic plasmid DNA. It does this by simultaneously detecting two targets within the C trachomatis cryptic plasmid and genome target DNA. Plasmids are outside a bacteria's chromosomal DNA and are capable of replicating independently. The test is run on the Cobas TaqMan 48 analyser, which can carry out 48 tests per run with results available in 2.5 hours.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043477

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel